Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.884
+0.032 (3.75%)
Dec 5, 2025, 4:00 PM EST - Market closed
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
3.68M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OGEN News
- 23 days ago - Oragenics Q3 2025 Shareholder Update - Business Wire
- 6 weeks ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire
- 2 months ago - Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Business Wire
- 4 months ago - Oragenics Q2 2025 Shareholder Update - GlobeNewsWire
- 5 months ago - Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - GlobeNewsWire
- 5 months ago - Oragenics Completes Approximately $16.5 Million Offering - GlobeNewsWire
- 5 months ago - Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - GlobeNewsWire
- 7 months ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire